Bicycle Therapeutics, co-founded by blockbuster drug developer, raises £40m
The top blockbuster drug for 2016 was based on the techniques developed by Professor Sir Gregory Winter. Now his latest Cambridge company, Bicycle Therapeutics, has gained £40 million from investors including Cambridge Innovation Capital.
Cambridge Innovation Capital provides a solution to the ‘scale-up chasm’ for start-ups
Cambridge Innovation Capital (CIC), a Cambridge-based investor in technology and healthcare companies, announces that its CEO, Victor Christou, will be presenting at the Global University Venturing: Fusion event in London this evening (Weds).
Cambridge Innovation Capital supports Congenica's international ambitions
Seventy-five per cent of patients with a rare disease are children. Cambridge-based Congenica has a world-leading technology that offers a rapid diagnosis. Already in clinical use in the UK, the company has raised £8 million to fund its international expansion.
CIC appoints Dr Michael Anstey as Investment Director
Cambridge Innovation Capital plc is pleased to announce the appointment of Dr Michael Anstey as an Investment Director specialising in healthcare investments.
CIC and IP Group announce creation of Sanger Institute spinout with £8m funding
The creation of Microbiotica Ltd, a newly formed spin-out company from the UK’s Wellcome Trust Sanger Institute based at the Wellcome Genome Campus in Hinxton, Cambridge, has been announced by Cambridge Innovation Capital plc (CIC), a Cambridge-based investor in technology and healthcare companies, and IP Group plc, the developer of intellectual property-based businesses.
Cambridge Innovation Capital appoints Dr Andrew Williamson as Investment Director
Cambridge Innovation Capital plc (CIC), a Cambridge-based investor in technology and healthcare companies, is pleased to announce the appointment of Dr Andrew Williamson as an Investment Director.
CIC commits £19 million to six recent investments
Cambridge Innovation Capital plc has committed £19 million to six investments since raising £75 million in August 2016. The £75 million funding round increased CIC’s funds under management to £125 million. CIC has provided funding to three existing portfolio companies, Imagen, PragmatIC Printing and Undo, and three new businesses, Carrick Therapeutics, Fluidic Analytics and PervasID.
Undo raises $3.3m in series A financing led by CIC
Undo, the leading commercial supplier of next-generation software quality tools for Linux and Android developers, announced it has closed a $3.3 million Series A financing round. The round was led by Cambridge Innovation Capital (CIC), the Cambridge-based investor in technology companies.
PragmatIC gains £18m from ARM, CIC, Avery Dennison for flexible electronics production
PragmatIC develops flexible integrated circuits (FlexICs), thinner than a human hair, that can be incorporated into ‘smart packaging’ such as labels for consumer goods. Its technology is an enabler for the Internet of Things. The company has raised £18million to commercialise its FlexLogIC “fab-in-a-box” equipment which is a breakthrough in FlexIC manufacture. Investors include Avery Dennison,…
Carrick Therapeutics $95m funding round includes Cambridge Innovation Capital
Research from the Gurdon Institute in Cambridge has been licensed to Carrick Therapeutics, which has gained $95m from funders including Cambridge Innovation Capital (CIC). This is the second time within a few months that technology from the Gurdon Institute has gained funding from CIC.
Cambridge Innovation Capital raises £75 million via private financing
Cambridge Innovation Capital plc (CIC), a preferred investor for the University of Cambridge and a Cambridge-based investor in technology and healthcare companies, announces that it has raised £75m of new capital.
Robot assisted surgery closer as Cambridge Medical Robotics raises $20m
Cambridge Innovation Capital is one of the new investors for Cambridge Medical Robotics, which today announces that it has secured $20.3 million in Series A funding. Robot-assisted surgery can offer all the benefits of manual minimal access surgery while crucially making life easier for the surgeon, extending their careers, and at an affordable cost.
Storm Therapeutics raises £12m in Series 'A' funding
Cambridge Innovation Capital has invested in the Series ‘A’ funding round of Storm Therapeutics (formerly known as Iceni Therapeutics), a spin-out company from the University of Cambridge’s Gurdon Institute focused on the identification and development of small molecule drugs that target RNA-modifying enzymes. In total, Storm Therapeutics has secured £12 million from Cambridge Innovation Capital…
Origami Energy raises £13.7 million series ‘A’ funding
Origami Energy has raised £13.7 million series ‘A' funding to bring its distributed energy technology platform to market. The company - which enables the intelligent management of distributed energy assets - has raised funds from existing shareholders including Cambridge Innovation Capital and Octopus Ventures together with a new investment from Fred. Olsen related companies.
Listening lightbulb uses Audio Analytic's smart home tech
A smart lightbulb that can recognise the sound of an intruder breaking a window has won a major industry award, and this has fuelled further demand for Audio Analytic, the world's leading sound recognition company. To address its growing order book and fund new developments, the company has raised £1 million from investors including Cambridge Innovation Capital, IQ Capital Partners and Cambridge…
Inivata ‘liquid biopsy’ technology company raises £31.5M
Clinical cancer genomics company, Inivata, has announced the completion of a Series A fundraising of £31.5 Million, from investors including CIC. The company, a leader in circulating tumour DNA (ctDNA) analysis, has developed a 'liquid biopsy' which offers non-invasive molecular profiling from a simple blood draw.
Potentially transformative therapy for rare heart disease to be progressed by Morphogen-IX
Morphogen-IX, a new Cambridge-based biotech company, has gained seed funding to develop a new treatment for pulmonary arterial hypertension (PAH) that directly targets the major pathway implicated in human genetic studies.
Jukedeck MAKE computer-composed music prophecy come true
Jukedeck has chosen the 200th birthday of Ada Lovelace – who predicted that a computer programme would be able to write music – to launch its first product ‘Jukedeck MAKE’, seal a partnership with music tech incubator, Abbey Road Red and celebrate a further injection of £2m funding led by Cambridge Innovation Capital (CIC).
Jukedeck gains £2m follow-on funding led by Cambridge Innovation Capital
Digital music creator Jukedeck has gained £2m follow-on funding in a round led by Cambridge Innovation Capital and announced its first product Jukedeck MAKE.
Silicon Fen is a good place to have a business, Muller tells CNBC
Silicon Valley is not the only place to have tech success, says ARM co-founder Mike Muller in his interview with the news channel CNBC. He explains that UK can compete with the US tech hub from its own Silicon Fen.
Abcodia secures £5.25M for ovarian cancer test
Abcodia today announced that it has raised £5.25million funding from existing and new investors to bring the world's most sensitive and specific ovarian cancer screening test, ROCA® to market. Cambridge Innovation Capital and Scottish Equity Partners co-led the funding round.
Undo 'turns back time' to find bugs that eat 50% of development time
Undo, producers of debugging tools that could save the industry $81bn a year by ‘turning back time’ to find the origins of software problems, has announced it has raised $2m in funding from Cambridge Innovation Capital (CIC), Cambridge Angels, Jaan Tallinn (co-founder of Skype) and Sir Peter Michael (founder of Classic FM), to accelerate its growth.
Genome diagnostic company Congenica raises £2.2m
Cambridge-based Congenica, a spinout from The Wellcome Trust Sanger Institute, has raised a further £2.2m with the completion of a series A round of financing by Amadeus Capital Partners’ early stage funds and the company’s initial investor Cambridge Innovation Capital.
Diagnosis of rare genetic diseases boosted as Congenica gains £2m Genomics England SBRI
Currently many children with rare genetic disorders caused by single gene mutations do not have a specific diagnosis. To help address this issue Congenica – a spinout from the Wellcome Trust Sanger Institute – has been awarded £2m Phase 2 funding by the Small Business Research Initiative (SBRI) announced today by Genomics England.
Definitive diagnosis of rare genetic diseases possible in minutes, says Congenica
Definitive diagnosis of children with rare genetic diseases may soon take minutes rather than years following the announcement that Congenica, the genome discovery and diagnostics company, has gained up to £1M seed funding from Cambridge Innovation Capital to scale up its SapientiaTM analysis platform to support a clinical diagnostic service.